<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2017.6112</article-id>
<article-id pub-id-type="publisher-id">or-39-02-0545</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>miR-328-3p enhances the radiosensitivity of osteosarcoma and regulates apoptosis and cell viability via <italic>H2AX</italic></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Yang</surname><given-names>Zhen</given-names></name>
<xref rid="af1-or-39-02-0545" ref-type="aff">1</xref>
<xref rid="fn1-or-39-02-0545" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Wa</surname><given-names>Qing-De</given-names></name>
<xref rid="af2-or-39-02-0545" ref-type="aff">2</xref>
<xref rid="fn1-or-39-02-0545" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Lu</surname><given-names>Chao</given-names></name>
<xref rid="af1-or-39-02-0545" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Pan</surname><given-names>Wei</given-names></name>
<xref rid="af1-or-39-02-0545" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Lu</surname><given-names>Zi-Mo</given-names></name>
<xref rid="af2-or-39-02-0545" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Ao</surname><given-names>Jun</given-names></name>
<xref rid="af2-or-39-02-0545" ref-type="aff">2</xref>
<xref rid="c1-or-39-02-0545" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-or-39-02-0545"><label>1</label>Guizhou Provincial People&#x0027;s Hospital, Guiyang, Guizhou, P.R. China</aff>
<aff id="af2-or-39-02-0545"><label>2</label>Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou, P.R. China</aff>
<author-notes>
<corresp id="c1-or-39-02-0545"><italic>Correspondence to</italic>: Professor Jun Ao, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563003, P.R. China, E-mail: <email>ao00jun@163.com</email></corresp>
<fn id="fn1-or-39-02-0545"><label>&#x002A;</label><p>Contributed equally</p></fn>
</author-notes>
<pub-date pub-type="ppub"><month>02</month><year>2018</year></pub-date>
<pub-date pub-type="epub"><day>27</day><month>11</month><year>2017</year></pub-date>
<volume>39</volume>
<issue>2</issue>
<fpage>545</fpage>
<lpage>553</lpage>
<history>
<date date-type="received"><day>26</day><month>12</month><year>2016</year></date>
<date date-type="accepted"><day>26</day><month>09</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Yang et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Osteosarcoma is a kind of high-risk sarcoma of the skeleton typically observed in people under 25 years old. Currently, radiotherapy is widely applied in cancer treatment. However, osteosarcoma is radioresistant and accordingly new, more effective radiosensitizers are needed. miRNAs have been reported to play an important role in osteosarcoma radiosensitivity. We examined the modulating effect of miR-328-3p <italic>in vivo</italic> and <italic>in vitro</italic>. miR-328-3p was downregulated in HOS-2R cells. The overexpression of miR-328-3p enhanced the radiosensitivity of osteosarcoma cells. miR-328-3p inhibited proliferation and promoted apoptosis in osteosarcoma cells under radiation conditions. In cells overexpressing miR-328-3p, <italic>H2AX</italic> expression was downregulated. We found that miR-328-3p targets <italic>H2AX</italic> and inhibits its expression. It was concluded, that miR-328-3p enhances the radiosensitization of osteosarcoma following X-ray irradiation, and determined that it directly targets <italic>H2AX</italic> to regulate radiosensitization.</p>
</abstract>
<kwd-group>
<kwd>miR-328-3p</kwd>
<kwd>radiosensitivity</kwd>
<kwd>osteosarcoma</kwd>
<kwd><italic>H2AX</italic></kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Osteosarcoma (OS) originates from the metaphyseal areas of the long bones and is a frequently occurring disease in children, adolescents, and young adults (<xref rid="b1-or-39-02-0545" ref-type="bibr">1</xref>,<xref rid="b2-or-39-02-0545" ref-type="bibr">2</xref>). The risk of developing OS is highest among people under 25 years old and second-highest in individuals aged 60&#x2013;80 years (<xref rid="b3-or-39-02-0545" ref-type="bibr">3</xref>,<xref rid="b4-or-39-02-0545" ref-type="bibr">4</xref>). Before the 1970s, the mortality rate was ~80&#x0025; because surgery was the only method for OS treatment. With advances in surgical techniques and the emergence of chemotherapy, the disease-free survival rate has improved substantially (<xref rid="b5-or-39-02-0545" ref-type="bibr">5</xref>,<xref rid="b6-or-39-02-0545" ref-type="bibr">6</xref>). In response to tumor metastasis, radiotherapy has emerged as a more efficient treatment (<xref rid="b7-or-39-02-0545" ref-type="bibr">7</xref>,<xref rid="b8-or-39-02-0545" ref-type="bibr">8</xref>). However, radiotherapy to treat OS is limited by radioresistance (<xref rid="b9-or-39-02-0545" ref-type="bibr">9</xref>,<xref rid="b10-or-39-02-0545" ref-type="bibr">10</xref>). Therefore, it is necessary to study the molecular mechanism of OS radioresistance to improve the efficiency of OS radiotherapy. Ionizing radiation can activate reactive oxygen species (ROS) and cause oxidative damage to DNA bases. DNA double-strand breaks (DSB) have a dual influence on tumor therapy; they can lead to cancer, but can also kill cancer cells. The phosphorylation of histone H2AX is a sensitive marker for DSB (<xref rid="b11-or-39-02-0545" ref-type="bibr">11</xref>) and H2AX contributes to DSB repair (<xref rid="b12-or-39-02-0545" ref-type="bibr">12</xref>). The expression level of phospho-H2AX (pH2AX) contributes to the detection of epithelial ovarian cancer (<xref rid="b13-or-39-02-0545" ref-type="bibr">13</xref>). &#x03B3;H2AX plays an important role in the response to DSB and participates in the DSB repair process mediated by DNA repair enzymes (<xref rid="b14-or-39-02-0545" ref-type="bibr">14</xref>).</p>
<p>MicroRNAs (miRNAs) are short (18&#x2013;24 nucleotides) single-stranded non-coding RNAs; they cannot be translated into proteins or oligopeptides. In some cases, miRNAs can post-transcriptionally regulate gene expression by binding to the target site in mRNA (<xref rid="b15-or-39-02-0545" ref-type="bibr">15</xref>,<xref rid="b16-or-39-02-0545" ref-type="bibr">16</xref>). Some studies have found that miRNAs are involved in the process of tumor development. The overexpression of miR-187 can inhibit colorectal cancer progression by directly targeting <italic>CD276</italic> (<xref rid="b17-or-39-02-0545" ref-type="bibr">17</xref>). In OS, miR-489-3p is downregulated and the overexpression of miR-489-3p can suppress OS progression by targeting <italic>PAX3</italic> (<xref rid="b18-or-39-02-0545" ref-type="bibr">18</xref>). Recent research has indicated that miRNAs are also involved in tumor radioresistance. miR-185 can target ATR (rad3-related), which can respond to DNA damage and DNA replication stress, enhancing radiosensitivity in tumor cells (<xref rid="b19-or-39-02-0545" ref-type="bibr">19</xref>). In esophageal squamous cell carcinoma, the expression level of miR-98 is positively correlated with radiosensitivity (<xref rid="b20-or-39-02-0545" ref-type="bibr">20</xref>). In cervical cancer cells, miR-424 can target aprataxin and the overexpression of miR-424 can increase the cell sensitivity to radiation (<xref rid="b21-or-39-02-0545" ref-type="bibr">21</xref>).</p>
<p>In our previous study, miR-328-3p expression was distinctly reduced in a radiation-tolerant HOS cell line (HOS-2R) (<xref rid="f1-or-39-02-0545" ref-type="fig">Fig. 1</xref>). We hypothesized that miR-328-3p plays a role in the development of OS cells. In the present study, we examined the correlation between miR-328-3p and radioresistance in OS cells <italic>in vivo</italic> and <italic>in vitro</italic>. We determined the regulatory role of miR-328-3p in OS radioresistance by overexpressing or knocking out miR-328-3p in OS cell lines, and we showed that miR-328-3p targets <italic>H2AX</italic> to enhance OS radiosensitivity.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell culture, irradiation, and transfection</title>
<p>The human osteosarcoma cell line HOS was purchased from the Cell Culture Center, Institute of Basic Medical Sciences (Beijing, China). U2-OS cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cultures of the cell lines were maintained in a humidified, 37&#x00B0;C, 5&#x0025; CO<sub>2</sub> incubator. McCoy&#x0027;s 5A Media (modified with Tricine) (Sigma, St. Louis, MO, USA) with 10&#x0025; FBS (Gibco, Grand Island, NY, USA) was used for cell culture. The cells in exponential growth were exposed to X-ray radiation at 2, 4 or 8 Gy at room temperature to measure radioresistance <italic>in vitro</italic>. An X-ray machine (Faxitron RX-650; Tucson, AZ, USA) with 100 kVp (0.835 Gy/min) was used for irradiation.</p>
<p>Cells were transfected with miRNA mimics and a control, i.e., miR-328-3p mimics, miR-328-3p ASO (anti-miRNA oligos), or ASO control (RiboBio, Guangzhou, China). Additionally, siRNA-<italic>H2AX</italic> and siRNA control were purchased from GeneChem (Shanghai, China).</p>
</sec>
<sec>
<title>Establishment of radioresistant cell lines</title>
<p>HOS cells (2&#x00D7;10<sup>6</sup>) were cultured in McCoy&#x0027;s 5A Media supplemented with 10&#x0025; FBS. Ten minutes before irradiation, the cells were replaced with fresh medium, then cells were irradiated by an X-ray machine (0.835 Gy/min) with 2 Gy dose. To obtain radioresistant cell population, a total dose of 44 Gy was reached by 22 fractions of irradiation. Each time after irradiation, the culture medium was replaced with fresh complete medium. When the cell confluence reached &#x003E;80&#x0025;, the cells were subcultured. Additionally, the next irradiation was performed when the cell confluence reached 50&#x0025;.</p>
</sec>
<sec>
<title>Quantitative real-time PCR</title>
<p>Total RNA was extracted from OS cell lines using TRIzol LS reagent (Invitrogen, Carlsbad, CA, USA) and cDNA was synthesized using the TaqMan miRNA Reverse Transcription kit (Applied Biosystems, Waltham, MA, USA). Then, the cDNA was amplified for 28 cycles in a PCR machine (Roche): 94&#x00B0;C for 30 sec; annealing for 30 sec, 72&#x00B0;C for 30 sec. Quantitative real-time PCR (qRT-PCR) analyses were performed with SYBR<sup>&#x00AE;</sup> Premix Ex Taq&#x2122; (Takara, Japan) using a StepOne-plus Real-Time PCR System (Applied Biosystems). The PCR cycling was as follows: 95&#x00B0;C for 2 min, 40 cycles of 95&#x00B0;C for 10 sec, 60&#x00B0;C for 20 sec, 72&#x00B0;C for 20 sec. The relative expression levels of miRNAs were calculated using the 2<sup>&#x2212;&#x2206;&#x2206;Ct</sup> method. U6 snRNA was used as internal controls to normalize the expression levels of miRNAs. The qPCR primers for miR-328-3p were as follows: F-5&#x2032;-TGCGGCTGGCCCTCTCTGCCC-3&#x2032;; R-5&#x2032;-CCAGTGCAGGGTCCGAGGT-3&#x2032;. The qPCR primers for U6 snRNA were as follows: F-5&#x2032;-TGCGGGTGCTCGCTTCGGCAGC-3&#x2032;; R-5&#x2032;-CCAGTGCAGGGTCCGAGGT-3&#x2032;.</p>
</sec>
<sec>
<title>MTT assay</title>
<p>The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay was performed to measure the viability of osteosarcoma cells using the Cell Proliferation Kit I (Sigma), following the procedure described in the kit manual. Cells were grown in 96-wells in a final volume of 100 &#x00B5;l of culture medium per well in a humidified 37&#x00B0;C incubator. MTT labeling reagent was added to each well to obtain a final concentration of 0.5 mg/ml. Samples were incubated for 4 h in a humidified atmosphere. Then, 100 &#x00B5;l of solubilization solution was added to each well, followed by incubation (37&#x00B0;C) overnight. Absorbance of the samples was measured spectrophotometrically using a microplate reader.</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>Cells were scraped from the wells after washing twice with cold PBS. Total proteins were extracted using ice-cold RIPA lysis buffer (Solarbio, Beijing, China) with a protease inhibitor. Then, 40 &#x00B5;g of total proteins from each sample was subjected to 12&#x0025; SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). After samples were washed and blocked with 5&#x0025; non-fat milk, the membrane was incubated with the primary antibodies (Abcam, UK). After they were washed in TBS, the membrane was treated with a horseradish peroxidase-conjugated secondary antibody (ICLLAB, USA). Proteins were observed by chemiluminescence (Millipore, Billerica, MA, USA).</p>
</sec>
<sec>
<title>Survival colony formation assay</title>
<p>Cell suspensions were exposed to X-ray radiation; then, 1&#x00D7;10<sup>6</sup> cells were seeded in 6-well plates and cultured for 12 days. Detailed cultivation methods are described above (Cell culture and irradiation). The number of colonies that contained at least 50 cells was counted.</p>
</sec>
<sec>
<title>Apoptosis</title>
<p>Cells (1&#x00D7;10<sup>7</sup>) were washed with cold PBS and fixed in cold 70&#x0025; ethanol overnight at &#x2212;20&#x00B0;C. The Annexin V-FITC Apoptosis Detection kit (Abcam) was used to perform apoptosis assays following the manufacturer&#x0027;s instructions. The samples were analyzed using the FACS III (BD Biosciences, Franklin Lakes, NJ, USA).</p>
</sec>
<sec>
<title>Tumor xenograft assay</title>
<p>Female nude mice (BALB/c, 5 weeks old) were purchased from Nanjing Biomedical Research Institute of Nanjing University (Nanjing, China) and housed under SPF conditions. All animal experiments were approved by the Institutional Animal Care and Use Committee of Guizhou Provincial People&#x0027;s Hospital (Guizhou, China).</p>
<p>The mouse tumor xenograft model was established; 1&#x00D7;10<sup>7</sup> HOS cells were suspended in 0.1 ml of PBS and subcutaneously injected into the right thigh of the nude mice. Ten days later, the mice were intratumorally injected with 5 nmol miR-328-3p agomir or 5 nmol miR-NC agomir at days 12, 16, 20, 24, 28 and 32. Mice were exposed to 4 Gy of X-ray radiation after each intratumoral injection. At day 34, the mice were sacrificed by cervical dislocation. The tumor weight was measured using electronic scales (Sartorius, Beijing, China), and the tumor volume was calculated as length &#x00D7; (width)<sup>2</sup>/2.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>One-way ANOVA was performed to determine the statistical significance of differences between groups. The numerical results are presented as means &#x00B1; standard deviation. Differences with a p-value of &#x003C;0.05 were considered statistically significant.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Modulation of miR-328-3p alters the radiosensitivity of osteosarcoma cells</title>
<p>HOS and U2OS are human osteosarcoma cell lines, we used these two kinds of cells to explore the effect of miR-328-3p on the radiosensitivity of osteosarcoma cells. In order to investigate the relationship between miR-328-3p and radiosensitivity in OS cells, we also established radiation-tolerant HOS cell lines (HOS-2R) by X-ray (2 Gy). miR-328-3p levels in HOS-2R cells were detected by qPCR and the expression levels were downregulated compared with those in control cells (<xref rid="f1-or-39-02-0545" ref-type="fig">Fig. 1A</xref>). To explore whether the modulation of miR-328-3p affects the radiosensitivity of OS cells, we also performed an MTT assay to determine the survival rate of HOS-2R cells, HOS cells, and U2OS cells following irradiation at 0 or 8 Gy. The overexpression of miR-328-3p reduced HOS-2R cell viability following 8 Gy of X-ray, and there was no significant difference between miRNA control and miR-328-3p mimic groups following irradiation with 0 Gy (<xref rid="f1-or-39-02-0545" ref-type="fig">Fig. 1B</xref>). Then, we silenced miR-328-3p in HOS and U2OS cells using antisense oligonucleotides (ASO). The deletion of miR-328-3p increased the viability of HOS cells following 8-Gy irradiation (<xref rid="f1-or-39-02-0545" ref-type="fig">Fig. 1C</xref>), similar to the results obtained for U2OS cells (<xref rid="f1-or-39-02-0545" ref-type="fig">Fig. 1D</xref>). These results confirmed that miR-328-3p has a regulatory role in OS cell radiosensitivity.</p>
</sec>
<sec>
<title>miR-328-3p increases the rate of apoptosis and reduces the proliferation ability of osteosarcoma cells after ionizing radiation</title>
<p>Based on the observation that the abnormal expression of miR-328-3p alters the radiosensitivity of OS cells, we examined whether miR-328-3p influences the apoptosis and proliferation of OS cells. Radioresistant cell lines were established under the condition of 2-Gy irradiation, so we need to increase the dose of X-ray to 4 Gy. Compared to HOS-2R, HOS and U2OS was more sensitive to irradiation. 2 Gy X-ray exposure was enough to investigate the biological characteristics of HOS and U2OS cells. miR-328-3p was overexpressed in HOS-2R cells, and the number of surviving clones after X-ray exposure at 0 or 4 Gy was counted. The surviving clone number for HOS-2R cells overexpressing miR-328-3p decreased following irradiation at 4 Gy (<xref rid="f2-or-39-02-0545" ref-type="fig">Fig. 2A</xref>). Then, we inhibited the expression of miR-328-3p in HOS and U2OS cells using miR-328-3p ASO. The deficiency of miR-328-3p increased the survival rate after X-ray exposure at 2 Gy, both in HOS and U2OS cells (<xref rid="f2-or-39-02-0545" ref-type="fig">Fig. 2B</xref>). Apoptosis was analyzed by flow cytometry following miR-328-3p overexpression or knockout in various cell types (including HOS-2R, HOS and U2OS cells). The overexpression of miR-328-3p enhanced HOS-2R cell apoptosis after exposure to 4 Gy (<xref rid="f2-or-39-02-0545" ref-type="fig">Fig. 2C</xref>). In HOS and U2OS cells in which miR-328-3p was knocked out, apoptosis decreased after exposure to 2 Gy (<xref rid="f2-or-39-02-0545" ref-type="fig">Fig. 2D</xref>). These results confirmed that miR-328-3p inhibits proliferation and promotes apoptosis in OS cells under radiation conditions, and miR-328-3p enhances the radiosensitivity of OS.</p>
</sec>
<sec>
<title>miR-328-3p targets H2AX and inhibits its expression</title>
<p>Using the bioinformatics tool TargetScan, we determined that H2AX is a predicted target for miR-328-3p. As shown in <xref rid="f3-or-39-02-0545" ref-type="fig">Fig. 3A</xref>, the 3&#x2032;-UTR region of <italic>H2AX</italic> contains a sequence that matches the specific binding sequences of miR-328-3p. A luciferase reporter assay was used to further prove the targeting of miR-328-3p to the <italic>H2AX</italic> 3&#x2032;-UTR. The cotransfection of miR-328-3p mimics with the wild-type vector reduced luciferase activity in HOS cells compared to that of control-treated cells, and a similar trend was found in U2OS cells (<xref rid="f3-or-39-02-0545" ref-type="fig">Fig. 3B</xref>). No statistically significant differences in luciferase activity were observed for cells cotransfected with miR-328-3p mimics and mutant vector compared to control-treated cells (<xref rid="f3-or-39-02-0545" ref-type="fig">Fig. 3B</xref>). We also detected the expression levels of <italic>H2AX</italic> in HOS-2R and HOS cells by western blotting, and HOS-2R cells had a higher level of <italic>H2AX</italic> expression compared to that of HOS cells (<xref rid="f3-or-39-02-0545" ref-type="fig">Fig. 3C</xref>), in contrast to the miR-328-3p expression patterns (<xref rid="f1-or-39-02-0545" ref-type="fig">Fig. 1A</xref>). To explore the miR-328-3p regulatory effect on <italic>H2AX</italic>, we used HOS and U2OS cell lines. We detected the expression levels of <italic>H2AX</italic> by western blotting after overexpressing or silencing miR-328-3p. We found that the expression of <italic>H2AX</italic> was suppressed after miR-328-3p mimic transfection in HOS cells. When miR-328-3p was knocked out using miR-328-3p ASO, the expression of <italic>H2AX</italic> increased. A similar phenomenon was observed in U2OS cells (<xref rid="f3-or-39-02-0545" ref-type="fig">Fig. 3D</xref>). These results showed that miR-328-3p targets <italic>H2AX</italic>, and the modulation of miR-328-3p affects the expression of <italic>H2AX</italic>.</p>
</sec>
<sec>
<title>miR-328-3p mediates the radiosensitivity of osteosarcoma cells by targeting H2AX</title>
<p>We knocked out <italic>H2AX</italic> using <italic>H2AX</italic> siRNA in the HOS and U2OS cell lines. We verified the knockout efficiency by western blotting (<xref rid="f4-or-39-02-0545" ref-type="fig">Fig. 4A</xref>). The survival rate of <italic>H2AX</italic>-deficient HOS cells was reduced following irradiation at 2 Gy compared to that of sham-treated cells (<xref rid="f4-or-39-02-0545" ref-type="fig">Fig. 4B</xref>). A similar trend was also found in U2OS cells (<xref rid="f4-or-39-02-0545" ref-type="fig">Fig. 4B</xref>). To explore the effect of <italic>H2AX</italic> expression changes on apoptosis in OS cell lines, we examined apoptosis using a flow cytometry assay. Under radiation conditions of 2 Gy, <italic>H2AX</italic> deletion increased apoptosis in both HOS and U2OS cells (<xref rid="f4-or-39-02-0545" ref-type="fig">Fig. 4C</xref>). We also found that deleting <italic>H2AX</italic> reduced cell viability following irradiation at 2 Gy in both HOS and U2OS cells (<xref rid="f4-or-39-02-0545" ref-type="fig">Fig. 4D</xref>). Taken together, these results showed that deleting <italic>H2AX</italic> increases the radiosensitivity of OS cell lines.</p>
<p>To further study the function of miR-328-3p targeted to <italic>H2AX</italic>, we detected the cell sensitivity to radiation by western blotting. Cells were transfected with ASO con (control), miR-328-3p ASO, miR-328-3p ASO&#x002B;siRNA con or miR-328-3p ASO&#x002B;<italic>H2AX</italic> siRNA, respectively. The expression levels of miR-328-3p were reduced in miR-328-3p ASO transfected, miR-328-3p ASO and siRNA con cotransfected, and miR-328-3p ASO and <italic>H2AX</italic> siRNA cotransfected HOS cells, similar to the results observed in U2OS cells (<xref rid="f5-or-39-02-0545" ref-type="fig">Fig. 5A</xref>). The expression levels of <italic>H2AX</italic> increased after silencing miR-328-3p in both HOS and U2OS cells (<xref rid="f5-or-39-02-0545" ref-type="fig">Fig. 5B</xref>). The deficiency of miR-328-3p decreased apoptosis after 2-Gy X-ray exposure in both HOS and U2OS cells (<xref rid="f5-or-39-02-0545" ref-type="fig">Fig. 5C</xref>). The effect of miR-328-3p knockout on reducing apoptosis was weakened after knocking out miR-328-3p and <italic>H2AX</italic> simultaneously (<xref rid="f5-or-39-02-0545" ref-type="fig">Fig. 5C</xref>). The deficiency of miR-328-3p increased the viability of both HOS and U2OS cells after 2-Gy X-ray irradiation (<xref rid="f5-or-39-02-0545" ref-type="fig">Fig. 5D</xref>). The enhanced cell viability after miR-328-3p knockout was weakened after knocking out miR-328-3p and <italic>H2AX</italic> simultaneously (<xref rid="f5-or-39-02-0545" ref-type="fig">Fig. 5D</xref>). These results showed that miR-328-3p targets <italic>H2AX</italic> and thereby miR-328-3p can participate in the regulation of OS radiosensitivity.</p>
</sec>
<sec>
<title>Overexpression of miR-328-3p enhances the radiosensitivity of osteosarcoma in mice</title>
<p>A xenograft tumor model was examined to further study the effect of miR-328-3p on the radiosensitivity of OS <italic>in vivo</italic>. To test tumor growth following irradiation at 4 Gy, we subcutaneously injected miRNA control transfected HOS-2R cells or miR-328-3p transfected HOS-2R cells into the right thigh of nude mice. In the miRNA con-transfected HOS-2R group (control group), tumor growth was checked. After irradiation at 4 Gy, tumors continued to grow in the control group. However, tumors in the miR-328-3p-transfected HOS-2R group grew substantially slower compared to tumor growth in the control group (<xref rid="f6-or-39-02-0545" ref-type="fig">Fig. 6</xref>). These data showed that miR-328-3p can promote growth restraint in OS after irradiation at 4 Gy in mice.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Some miRNAs can regulate cancer cell radiosensitivity to ionizing radiation, and downstream targets have been identified (<xref rid="b20-or-39-02-0545" ref-type="bibr">20</xref>&#x2013;<xref rid="b26-or-39-02-0545" ref-type="bibr">26</xref>). In our radiation-tolerant HOS cell line (HOS-2R), miR-328-3p was downregulated. A previous study showed that miR-328 can restrain proliferation and migration of pulmonary arterial smooth muscle cells by targeting PIM-1 (<xref rid="b27-or-39-02-0545" ref-type="bibr">27</xref>). In our study, we found a positive correlation between miR-328-3p and OS radiosensitivity. Overexpressed miR-328-3p in OS increases the rate of apoptosis and reduces the proliferation ability after irradiation. miRNAs cannot be translated into proteins or oligopeptides and they often combine with the target points in mRNA to regulate gene expression and further affect downstream pathways (<xref rid="b15-or-39-02-0545" ref-type="bibr">15</xref>). miR-494-3p can inhibit the expression of Bmil, which leads to cell aging and thus to increased radiosensitivity of oral squamous cell carcinoma cells (<xref rid="b28-or-39-02-0545" ref-type="bibr">28</xref>). In a study of radiation-resistant tumor glioblastoma multiforme, Guo <italic>et al</italic> found that miR-26a disturbs downstream pathways by inhibiting the expression of <italic>ATM</italic> via its 3&#x2032;-UTR (<xref rid="b29-or-39-02-0545" ref-type="bibr">29</xref>). In the SWI2/SNF2-family, helicase-like transcription factor (HLTF) is an ATP-dependent chromatin remodeling enzyme related to DNA damage repair. <italic>HLTF</italic> mRNA is a target of miR-145, by which miR-145 can enhance the radiosensitivity of cervical cancer cells (<xref rid="b30-or-39-02-0545" ref-type="bibr">30</xref>). These studies show that miRNA can take part in the development of cancer. Also, the regulated role of miRNAs in OS has been revealed in previous studies, such as miR-542-5p, miR-217, miR-182, miR-199a-3p and miR-153 related to the OS progression (<xref rid="b31-or-39-02-0545" ref-type="bibr">31</xref>&#x2013;<xref rid="b35-or-39-02-0545" ref-type="bibr">35</xref>).</p>
<p>These past results suggest that <italic>H2AX</italic> plays an important role in DSB (<xref rid="b11-or-39-02-0545" ref-type="bibr">11</xref>&#x2013;<xref rid="b13-or-39-02-0545" ref-type="bibr">13</xref>); <italic>H2AX</italic> is involved in maintaining genome stability, and provides a platform for repair factors to function (<xref rid="b14-or-39-02-0545" ref-type="bibr">14</xref>,<xref rid="b36-or-39-02-0545" ref-type="bibr">36</xref>&#x2013;<xref rid="b38-or-39-02-0545" ref-type="bibr">38</xref>). Ionizing radiation can cause DSBs and, subsequently, <italic>H2AX</italic> phosphorylation at Ser139 via ATM, generating <italic>&#x03B3;H2AX</italic> foci (<xref rid="b11-or-39-02-0545" ref-type="bibr">11</xref>,<xref rid="b37-or-39-02-0545" ref-type="bibr">37</xref>). We found that <italic>H2AX</italic> was knocked out, the survival rate and the viability of OS cells were both reduced and the apoptosis was increased following irradiation at 2 Gy. The imbalance of <italic>H2AX</italic> probably perturbed the progress of chromatin remodeling and DNA repair, thus affecting the radiation tolerance of OS cells. The phosphorylation of <italic>H2AX</italic> can promote genome stability and accelerated DSB repair (<xref rid="b12-or-39-02-0545" ref-type="bibr">12</xref>,<xref rid="b36-or-39-02-0545" ref-type="bibr">36</xref>). <italic>&#x03B3;H2AX</italic> plays a critical role in the formation of chromatin-remodeling complexes, and <italic>&#x03B3;H2AX</italic> also helps DNA repair enzymes function effectively (<xref rid="b14-or-39-02-0545" ref-type="bibr">14</xref>,<xref rid="b38-or-39-02-0545" ref-type="bibr">38</xref>). Liao <italic>et al</italic> found that STAT3 can promote the phosphorylation of H2AX and enhance the expression of GADD45&#x03B3; and MDC-1 after UV exposure, and STAT3 reduces DNA damage caused by UV (<xref rid="b39-or-39-02-0545" ref-type="bibr">39</xref>). The phosphorylation of H2AX promotes NBS1 expression at damage sites, and the acetylation of histone H2AX at Lys 5 is crucially important for the damaged chromatin-specific binding of NBS1 (<xref rid="b40-or-39-02-0545" ref-type="bibr">40</xref>).</p>
<p>We proved that miR-328-3p target to the <italic>H2AX</italic> 3&#x2032;-UTR. Previous studies have shown that <italic>H2AX</italic> is regulated by upstream miRNAs. For example, miR-138 directly targets the histone H2AX to modulate the DNA damage response (<xref rid="b41-or-39-02-0545" ref-type="bibr">41</xref>). Lin28 targets <italic>H2AX</italic>, and a deficiency of Lin28 increases radiosensitivity in breast cancer cells (<xref rid="b42-or-39-02-0545" ref-type="bibr">42</xref>). <italic>H2AX</italic> has one more upstream regulatory element: miR-328-3p. In addition, a negative correlation was found between <italic>H2AX</italic> expression and miR-328-3p level in HOS-2R cells. This tendency provided an indirect proof that <italic>H2AX</italic> is a target of miR-328-3p.</p>
<p>One limitation of our study was the inability to obtain clinical specimens for further verification of the effect of miR-328-3p in humans. We tested xenograft tumor growth in mice. The results are consistent with the experiments <italic>in vivo</italic>. In general, miR-328-3p is a positive regulatory factor in OS radiosensitivity by <italic>H2AX</italic>, and it is worthwhile to study the function of miRNAs to treat cancer by regulating downstream elements. miR-328-3p shows promise as a new potential therapy target in OS.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by The Youth Fund of Guizhou Provincial People&#x0027;s Hospital (GZSYQN[2015]06) and the National Natural Science Foundation of China (31660265).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="b1-or-39-02-0545"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longhi</surname><given-names>A</given-names></name><name><surname>Errani</surname><given-names>C</given-names></name><name><surname>De Paolis</surname><given-names>M</given-names></name><name><surname>Mercuri</surname><given-names>M</given-names></name><name><surname>Bacci</surname><given-names>G</given-names></name></person-group><article-title>Primary bone osteosarcoma in the pediatric age: State of the art</article-title><source>Cancer Treat Rev</source><volume>32</volume><fpage>423</fpage><lpage>436</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.ctrv.2006.05.005</pub-id><pub-id pub-id-type="pmid">16860938</pub-id></element-citation></ref>
<ref id="b2-or-39-02-0545"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picci</surname><given-names>P</given-names></name></person-group><article-title>Osteosarcoma (osteogenic sarcoma)</article-title><source>Orphanet J Rare Dis</source><volume>2</volume><fpage>6</fpage><year>2007</year><pub-id pub-id-type="doi">10.1186/1750-1172-2-6</pub-id><pub-id pub-id-type="pmid">17244349</pub-id><pub-id pub-id-type="pmcid">1794406</pub-id></element-citation></ref>
<ref id="b3-or-39-02-0545"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>PA</given-names></name><name><surname>Gorlick</surname><given-names>R</given-names></name></person-group><article-title>Osteosarcoma</article-title><source>Pediatr Clin North Am</source><volume>44</volume><fpage>973</fpage><lpage>989</lpage><year>1997</year><pub-id pub-id-type="doi">10.1016/S0031-3955(05)70540-X</pub-id><pub-id pub-id-type="pmid">9286295</pub-id></element-citation></ref>
<ref id="b4-or-39-02-0545"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorfman</surname><given-names>HD</given-names></name><name><surname>Czerniak</surname><given-names>B</given-names></name></person-group><article-title>Bone cancers</article-title><source>Cancer</source><volume>75</volume><supplement>Suppl</supplement><fpage>203</fpage><lpage>210</lpage><year>1995</year><pub-id pub-id-type="doi">10.1002/1097-0142(19950101)75:1+&#x003C;203::AID-CNCR2820751308&#x003E;3.0.CO;2-V</pub-id><pub-id pub-id-type="pmid">8000997</pub-id></element-citation></ref>
<ref id="b5-or-39-02-0545"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittig</surname><given-names>JC</given-names></name><name><surname>Bickels</surname><given-names>J</given-names></name><name><surname>Priebat</surname><given-names>D</given-names></name><name><surname>Jelinek</surname><given-names>J</given-names></name><name><surname>Kellar-Graney</surname><given-names>K</given-names></name><name><surname>Shmookler</surname><given-names>B</given-names></name><name><surname>Malawer</surname><given-names>MM</given-names></name></person-group><article-title>Osteosarcoma: A multidisciplinary approach to diagnosis and treatment</article-title><source>Am Fam Physician</source><volume>65</volume><fpage>1123</fpage><lpage>1132</lpage><year>2002</year><pub-id pub-id-type="pmid">11925089</pub-id></element-citation></ref>
<ref id="b6-or-39-02-0545"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>WS</given-names></name><name><surname>Goorin</surname><given-names>AM</given-names></name></person-group><article-title>Current treatment of osteosarcoma</article-title><source>Cancer Invest</source><volume>19</volume><fpage>292</fpage><lpage>315</lpage><year>2001</year><pub-id pub-id-type="doi">10.1081/CNV-100102557</pub-id><pub-id pub-id-type="pmid">11338887</pub-id></element-citation></ref>
<ref id="b7-or-39-02-0545"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ta</surname><given-names>HT</given-names></name><name><surname>Dass</surname><given-names>CR</given-names></name><name><surname>Choong</surname><given-names>PF</given-names></name><name><surname>Dunstan</surname><given-names>DE</given-names></name></person-group><article-title>Osteosarcoma treatment: State of the art</article-title><source>Cancer Metastasis Rev</source><volume>28</volume><fpage>247</fpage><lpage>263</lpage><year>2009</year><pub-id pub-id-type="doi">10.1007/s10555-009-9186-7</pub-id><pub-id pub-id-type="pmid">19214708</pub-id></element-citation></ref>
<ref id="b8-or-39-02-0545"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marina</surname><given-names>N</given-names></name><name><surname>Gebhardt</surname><given-names>M</given-names></name><name><surname>Teot</surname><given-names>L</given-names></name><name><surname>Gorlick</surname><given-names>R</given-names></name></person-group><article-title>Biology and therapeutic advances for pediatric osteosarcoma</article-title><source>Oncologist</source><volume>9</volume><fpage>422</fpage><lpage>441</lpage><year>2004</year><pub-id pub-id-type="doi">10.1634/theoncologist.9-4-422</pub-id><pub-id pub-id-type="pmid">15266096</pub-id></element-citation></ref>
<ref id="b9-or-39-02-0545"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>R</given-names></name><name><surname>Bruland</surname><given-names>O</given-names></name><name><surname>Cassoni</surname><given-names>A</given-names></name><name><surname>Schomberg</surname><given-names>P</given-names></name><name><surname>Bielack</surname><given-names>S</given-names></name></person-group><article-title>The role of radiotherapy in oseosarcoma</article-title><source>Cancer Treat Res</source><volume>152</volume><fpage>147</fpage><lpage>164</lpage><year>2009</year><pub-id pub-id-type="doi">10.1007/978-1-4419-0284-9_7</pub-id><pub-id pub-id-type="pmid">20213389</pub-id></element-citation></ref>
<ref id="b10-or-39-02-0545"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>PM</given-names></name><name><surname>Wiseman</surname><given-names>GA</given-names></name><name><surname>Erlandson</surname><given-names>L</given-names></name><name><surname>Rodriguez</surname><given-names>V</given-names></name><name><surname>Trotz</surname><given-names>B</given-names></name><name><surname>Dubansky</surname><given-names>SA</given-names></name><name><surname>Albritton</surname><given-names>K</given-names></name></person-group><article-title>Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma</article-title><source>Clin Cancer Res</source><volume>11</volume><fpage>6895</fpage><lpage>6900</lpage><year>2005</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0628</pub-id><pub-id pub-id-type="pmid">16203780</pub-id></element-citation></ref>
<ref id="b11-or-39-02-0545"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonner</surname><given-names>WM</given-names></name><name><surname>Redon</surname><given-names>CE</given-names></name><name><surname>Dickey</surname><given-names>JS</given-names></name><name><surname>Nakamura</surname><given-names>AJ</given-names></name><name><surname>Sedelnikova</surname><given-names>OA</given-names></name><name><surname>Solier</surname><given-names>S</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name></person-group><article-title>GammaH2AX and cancer</article-title><source>Nat Rev Cancer</source><volume>8</volume><fpage>957</fpage><lpage>967</lpage><year>2008</year><pub-id pub-id-type="doi">10.1038/nrc2523</pub-id><pub-id pub-id-type="pmid">19005492</pub-id><pub-id pub-id-type="pmcid">3094856</pub-id></element-citation></ref>
<ref id="b12-or-39-02-0545"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassing</surname><given-names>CH</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name></person-group><article-title>H2AX may function as an anchor to hold broken chromosomal DNA ends in close proximity</article-title><source>Cell Cycle</source><volume>3</volume><fpage>149</fpage><lpage>153</lpage><year>2004</year><pub-id pub-id-type="doi">10.4161/cc.3.2.684</pub-id><pub-id pub-id-type="pmid">14712078</pub-id></element-citation></ref>
<ref id="b13-or-39-02-0545"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Phospho-histone H2AX is a diagnostic and prognostic marker for epithelial ovarian cancer</article-title><source>Int J Clin Exp Pathol</source><volume>8</volume><fpage>5597</fpage><lpage>5602</lpage><year>2015</year><pub-id pub-id-type="pmid">26191270</pub-id><pub-id pub-id-type="pmcid">4503141</pub-id></element-citation></ref>
<ref id="b14-or-39-02-0545"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Attikum</surname><given-names>H</given-names></name><name><surname>Gasser</surname><given-names>SM</given-names></name></person-group><article-title>Crosstalk between histone modifications during the DNA damage response</article-title><source>Trends Cell Biol</source><volume>19</volume><fpage>207</fpage><lpage>217</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.tcb.2009.03.001</pub-id><pub-id pub-id-type="pmid">19342239</pub-id></element-citation></ref>
<ref id="b15-or-39-02-0545"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambros</surname><given-names>V</given-names></name></person-group><article-title>The functions of animal microRNAs</article-title><source>Nature</source><volume>431</volume><fpage>350</fpage><lpage>355</lpage><year>2004</year><pub-id pub-id-type="doi">10.1038/nature02871</pub-id><pub-id pub-id-type="pmid">15372042</pub-id></element-citation></ref>
<ref id="b16-or-39-02-0545"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penna</surname><given-names>E</given-names></name><name><surname>Orso</surname><given-names>F</given-names></name><name><surname>Cimino</surname><given-names>D</given-names></name><name><surname>Vercellino</surname><given-names>I</given-names></name><name><surname>Grassi</surname><given-names>E</given-names></name><name><surname>Quaglino</surname><given-names>E</given-names></name><name><surname>Turco</surname><given-names>E</given-names></name><name><surname>Taverna</surname><given-names>D</given-names></name></person-group><article-title>miR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR-148b downmodulation</article-title><source>Cancer Res</source><volume>73</volume><fpage>4098</fpage><lpage>4111</lpage><year>2013</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-3686</pub-id><pub-id pub-id-type="pmid">23667173</pub-id></element-citation></ref>
<ref id="b17-or-39-02-0545"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>ZS</given-names></name><name><surname>Zhong</surname><given-names>M</given-names></name><name><surname>Bian</surname><given-names>YH</given-names></name><name><surname>Mu</surname><given-names>YF</given-names></name><name><surname>Qin</surname><given-names>SL</given-names></name><name><surname>Yu</surname><given-names>MH</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name></person-group><article-title>MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer</article-title><source>Oncotarget</source><volume>7</volume><fpage>44266</fpage><lpage>44276</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.10023</pub-id><pub-id pub-id-type="pmid">27329595</pub-id><pub-id pub-id-type="pmcid">5190094</pub-id></element-citation></ref>
<ref id="b18-or-39-02-0545"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name></person-group><article-title>Loss of MicroRNA-489-3p promotes osteosarcoma metastasis by activating PAX3-MET pathway</article-title><source>Mol Carcinog</source><volume>56</volume><fpage>1312</fpage><lpage>1321</lpage><year>2017</year><pub-id pub-id-type="doi">10.1002/mc.22593</pub-id><pub-id pub-id-type="pmid">27859625</pub-id></element-citation></ref>
<ref id="b19-or-39-02-0545"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Ding</surname><given-names>N</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Yao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name></person-group><article-title>Repression of ATR pathway by miR-185 enhances radiation-induced apoptosis and proliferation inhibition</article-title><source>Cell Death Dis</source><volume>4</volume><fpage>e699</fpage><year>2013</year><pub-id pub-id-type="doi">10.1038/cddis.2013.227</pub-id><pub-id pub-id-type="pmid">23807228</pub-id><pub-id pub-id-type="pmcid">3702279</pub-id></element-citation></ref>
<ref id="b20-or-39-02-0545"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>QJ</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>YL</given-names></name><name><surname>Wang</surname><given-names>ZW</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>HB</given-names></name></person-group><article-title>Upregulation of microRNA-98 increases radiosensitivity in esophageal squamous cell carcinoma</article-title><source>J Radiat Res (Tokyo)</source><volume>57</volume><fpage>468</fpage><lpage>476</lpage><year>2016</year><pub-id pub-id-type="doi">10.1093/jrr/rrw068</pub-id></element-citation></ref>
<ref id="b21-or-39-02-0545"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Dai</surname><given-names>N</given-names></name><name><surname>Dai</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>CX</given-names></name><name><surname>Qing</surname><given-names>Y</given-names></name></person-group><article-title>miR-424 acts as a tumor radiosensitizer by targeting aprataxin in cervical cancer</article-title><source>Oncotarget</source><volume>7</volume><fpage>77508</fpage><lpage>77515</lpage><year>2016</year><pub-id pub-id-type="pmid">27769049</pub-id><pub-id pub-id-type="pmcid">5363600</pub-id></element-citation></ref>
<ref id="b22-or-39-02-0545"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>QQ</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name></person-group><article-title>miR-124 radiosensitizes human esophageal cancer cell TE-1 by targeting CDK4</article-title><source>Genet Mol Res</source><volume>15</volume><year>2016</year></element-citation></ref>
<ref id="b23-or-39-02-0545"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name></person-group><article-title>MiR-21 modulates radiosensitivity of cervical cancer through inhibiting autophagy via the PTEN/Akt/HIF-1alpha feedback loop and the Akt-mTOR signaling pathway</article-title><source>Tumour Biol</source><volume>37</volume><fpage>12161</fpage><lpage>12168</lpage><year>2016</year><pub-id pub-id-type="doi">10.1007/s13277-016-5073-3</pub-id><pub-id pub-id-type="pmid">27220494</pub-id></element-citation></ref>
<ref id="b24-or-39-02-0545"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Si</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Gan</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>MicroRNA-449a enhances radiosensitivity by downregulation of c-Myc in prostate cancer cells</article-title><source>Sci Rep</source><volume>6</volume><fpage>27346</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/srep27346</pub-id><pub-id pub-id-type="pmid">27250340</pub-id><pub-id pub-id-type="pmcid">4890029</pub-id></element-citation></ref>
<ref id="b25-or-39-02-0545"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>SM</given-names></name><name><surname>Xia</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>YQ</given-names></name><name><surname>Sun</surname><given-names>AM</given-names></name><name><surname>Shi</surname><given-names>YS</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>LH</given-names></name></person-group><article-title>miR-124 regulates radiosensitivity of colorectal cancer cells by targeting PRRX1</article-title><source>Nan Fang Yi Ke Da Xue Xue Bao</source><volume>36</volume><fpage>1110</fpage><lpage>1116</lpage><year>2016</year> <comment>(In Chinese)</comment><pub-id pub-id-type="pmid">27578582</pub-id></element-citation></ref>
<ref id="b26-or-39-02-0545"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>C</given-names></name><name><surname>Meng</surname><given-names>G</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name></person-group><article-title>HLF/miR-132/TTK axis regulates cell proliferation, metastasis and radiosensitivity of glioma cells</article-title><source>Biomed Pharmacother</source><volume>83</volume><fpage>898</fpage><lpage>904</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.biopha.2016.08.004</pub-id><pub-id pub-id-type="pmid">27522003</pub-id></element-citation></ref>
<ref id="b27-or-39-02-0545"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>K</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhai</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Gou</surname><given-names>D</given-names></name></person-group><article-title>MiR-328 targeting PIM-1 inhibits proliferation and migration of pulmonary arterial smooth muscle cells in PDGFBB signaling pathway</article-title><source>Oncotarget</source><volume>7</volume><fpage>54998</fpage><lpage>55011</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.10714</pub-id><pub-id pub-id-type="pmid">27448984</pub-id><pub-id pub-id-type="pmcid">5342397</pub-id></element-citation></ref>
<ref id="b28-or-39-02-0545"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>JH</given-names></name><name><surname>Yu</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Lin</surname><given-names>CW</given-names></name><name><surname>Chang</surname><given-names>WW</given-names></name><name><surname>Kuo</surname><given-names>YL</given-names></name></person-group><article-title>miR-494-3p induces cellular senescence and enhances radiosensitivity in human oral squamous carcinoma cells</article-title><source>Int J Mol Sci</source><volume>17</volume><fpage>E1092</fpage><year>2016</year><pub-id pub-id-type="doi">10.3390/ijms17071092</pub-id><pub-id pub-id-type="pmid">27399693</pub-id></element-citation></ref>
<ref id="b29-or-39-02-0545"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Lan</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Nie</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>Q</given-names></name></person-group><article-title>MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated</article-title><source>Exp Cell Res</source><volume>320</volume><fpage>200</fpage><lpage>208</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.yexcr.2013.10.020</pub-id><pub-id pub-id-type="pmid">24211747</pub-id></element-citation></ref>
<ref id="b30-or-39-02-0545"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>NX</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>SB</given-names></name><name><surname>Sun</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells</article-title><source>FEBS Lett</source><volume>589</volume><fpage>702</fpage><lpage>709</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.febslet.2015.01.037</pub-id><pub-id pub-id-type="pmid">25666710</pub-id></element-citation></ref>
<ref id="b31-or-39-02-0545"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>DD</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Yao</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>CY</given-names></name><name><surname>Yang</surname><given-names>QC</given-names></name></person-group><article-title>MiR-542-5p is a negative prognostic factor and promotes osteosarcoma tumorigenesis by targeting HUWE1</article-title><source>Oncotarget</source><volume>6</volume><fpage>42761</fpage><lpage>42772</lpage><year>2015</year><pub-id pub-id-type="doi">10.18632/oncotarget.6199</pub-id><pub-id pub-id-type="pmid">26498360</pub-id><pub-id pub-id-type="pmcid">4767468</pub-id></element-citation></ref>
<ref id="b32-or-39-02-0545"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>MicroRNA-217 regulates WASF3 expression and suppresses tumor growth and metastasis in osteosarcoma</article-title><source>PLoS One</source><volume>9</volume><fpage>e109138</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0109138</pub-id><pub-id pub-id-type="pmid">25289936</pub-id><pub-id pub-id-type="pmcid">4188591</pub-id></element-citation></ref>
<ref id="b33-or-39-02-0545"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Nie</surname><given-names>B</given-names></name><name><surname>Duan</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name></person-group><article-title>The downregulation of miR-182 is associated with the growth and invasion of osteosarcoma cells through the regulation of TIAM1 expression</article-title><source>PLoS One</source><volume>10</volume><fpage>e0121175</fpage><year>2015</year><pub-id pub-id-type="doi">10.1371/journal.pone.0121175</pub-id><pub-id pub-id-type="pmid">25973950</pub-id><pub-id pub-id-type="pmcid">4431740</pub-id></element-citation></ref>
<ref id="b34-or-39-02-0545"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>JK</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Choy</surname><given-names>E</given-names></name><name><surname>Cote</surname><given-names>GM</given-names></name><name><surname>Harmon</surname><given-names>DC</given-names></name><name><surname>Mankin</surname><given-names>HJ</given-names></name><name><surname>Hornicek</surname><given-names>FJ</given-names></name><name><surname>Duan</surname><given-names>Z</given-names></name></person-group><article-title>CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma</article-title><source>Sci Rep</source><volume>5</volume><fpage>11365</fpage><year>2015</year><pub-id pub-id-type="doi">10.1038/srep11365</pub-id><pub-id pub-id-type="pmid">26079799</pub-id><pub-id pub-id-type="pmcid">4468826</pub-id></element-citation></ref>
<ref id="b35-or-39-02-0545"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>An</surname><given-names>C</given-names></name></person-group><article-title>MicroRNA-153 inhibits osteosarcoma cells proliferation and invasion by targeting TGF-&#x03B2;2</article-title><source>PLoS One</source><volume>10</volume><fpage>e0119225</fpage><year>2015</year><pub-id pub-id-type="doi">10.1371/journal.pone.0119225</pub-id><pub-id pub-id-type="pmid">25793604</pub-id><pub-id pub-id-type="pmcid">4368543</pub-id></element-citation></ref>
<ref id="b36-or-39-02-0545"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Capetillo</surname><given-names>O</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Nussenzweig</surname><given-names>M</given-names></name><name><surname>Nussenzweig</surname><given-names>A</given-names></name></person-group><article-title>H2AX: The histone guardian of the genome</article-title><source>DNA Repair (Amst)</source><volume>3</volume><fpage>959</fpage><lpage>967</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.dnarep.2004.03.024</pub-id><pub-id pub-id-type="pmid">15279782</pub-id></element-citation></ref>
<ref id="b37-or-39-02-0545"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stucki</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>SP</given-names></name></person-group><article-title>gammaH2AX and MDC1: Anchoring the DNA-damage-response machinery to broken chromosomes</article-title><source>DNA Repair (Amst)</source><volume>5</volume><fpage>534</fpage><lpage>543</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.dnarep.2006.01.012</pub-id><pub-id pub-id-type="pmid">16531125</pub-id></element-citation></ref>
<ref id="b38-or-39-02-0545"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinder</surname><given-names>JB</given-names></name><name><surname>Attwood</surname><given-names>KM</given-names></name><name><surname>Dellaire</surname><given-names>G</given-names></name></person-group><article-title>Reading, writing, and repair: The role of ubiquitin and the ubiquitin-like proteins in DNA damage signaling and repair</article-title><source>Front Genet</source><volume>4</volume><fpage>45</fpage><year>2013</year><pub-id pub-id-type="doi">10.3389/fgene.2013.00045</pub-id><pub-id pub-id-type="pmid">23554604</pub-id><pub-id pub-id-type="pmcid">3612592</pub-id></element-citation></ref>
<ref id="b39-or-39-02-0545"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>XH</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>HP</given-names></name><name><surname>Zheng</surname><given-names>DL</given-names></name><name><surname>Wei</surname><given-names>ZQ</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>WJ</given-names></name><name><surname>Zhang</surname><given-names>TC</given-names></name></person-group><article-title>STAT3 regulated ATR via microRNA-383 to control DNA damage to affect apoptosis in A431 cells</article-title><source>Cell Signal</source><volume>27</volume><fpage>2285</fpage><lpage>2295</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.cellsig.2015.08.005</pub-id><pub-id pub-id-type="pmid">26261078</pub-id></element-citation></ref>
<ref id="b40-or-39-02-0545"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikura</surname><given-names>M</given-names></name><name><surname>Furuya</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>S</given-names></name><name><surname>Matsuda</surname><given-names>R</given-names></name><name><surname>Shima</surname><given-names>H</given-names></name><name><surname>Adachi</surname><given-names>J</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Shiraki</surname><given-names>T</given-names></name><name><surname>Ikura</surname><given-names>T</given-names></name></person-group><article-title>Acetylation of histone H2AX at Lys 5 by the TIP60 histone acetyltransferase complex is essential for the dynamic binding of NBS1 to damaged chromatin</article-title><source>Mol Cell Biol</source><volume>35</volume><fpage>4147</fpage><lpage>4157</lpage><year>2015</year><pub-id pub-id-type="doi">10.1128/MCB.00757-15</pub-id><pub-id pub-id-type="pmid">26438602</pub-id><pub-id pub-id-type="pmcid">4648820</pub-id></element-citation></ref>
<ref id="b41-or-39-02-0545"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>JW</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Cavenee</surname><given-names>WK</given-names></name><name><surname>Mitchell</surname><given-names>PS</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Tewari</surname><given-names>M</given-names></name><name><surname>Furnari</surname><given-names>FB</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name></person-group><article-title>MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression</article-title><source>Mol Cancer Res</source><volume>9</volume><fpage>1100</fpage><lpage>1111</lpage><year>2011</year><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-11-0007</pub-id><pub-id pub-id-type="pmid">21693595</pub-id><pub-id pub-id-type="pmcid">3157593</pub-id></element-citation></ref>
<ref id="b42-or-39-02-0545"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>C</given-names></name><name><surname>Lv</surname><given-names>K</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name></person-group><article-title>Lin28 mediates radiation resistance of breast cancer cells via regulation of caspase, H2A.X and Let-7 signaling</article-title><source>PLoS One</source><volume>8</volume><fpage>e67373</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0067373</pub-id><pub-id pub-id-type="pmid">23840685</pub-id><pub-id pub-id-type="pmcid">3688678</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-or-39-02-0545" position="float">
<label>Figure 1.</label>
<caption><p>The expression level of miR-328-3p affects the radiosensitivity of osteosarcoma cells. (A) miR-328-3p expression levels were detected by qPCR in HOS and HOS-2R cells. HOS acted as controls, and radiation-tolerant HOS cell lines (HOS-2R) acted as IR (2 Gy) group which were established by 2 Gy X-ray irradiation. (B) Survival rate of HOS-2R overexpressing miR-328-3p was determined by an MTT assay after 8 Gy X-ray irradiation. (C and D) Survival rates of HOS and U2OS cells after silencing miR-328-3p were determined by an MTT assay after irradiation at 8 Gy. &#x002A;p&#x003C;0.05.</p></caption>
<graphic xlink:href="OR-39-02-0545-g00.jpg"/>
</fig>
<fig id="f2-or-39-02-0545" position="float">
<label>Figure 2.</label>
<caption><p>miR-328-3p enhanced X-ray-induced apoptosis and decreased the proliferation ability of osteosarcoma cells after X-ray exposure. (A) The number of surviving clones of miR-328-3p-overexpressing HOS-2R cells was counted after 0 or 4 Gy X-ray irradiation. (B) Survival rates of miR-328-3p ASO HOS and U2OS cells were estimated after 2 Gy X-ray irradiation. The apoptosis of HOS-2R cells overexpressing miR-328-3p (C) and HOS and U2OS cells with silenced miR-328-3p (D) was analyzed by flow cytometry following irradiation. &#x002A;p&#x003C;0.05.</p></caption>
<graphic xlink:href="OR-39-02-0545-g01.jpg"/>
</fig>
<fig id="f3-or-39-02-0545" position="float">
<label>Figure 3.</label>
<caption><p>miR-208b targets <italic>H2AX</italic> and represses <italic>H2AX</italic> expression by binding to its 3&#x2032;-UTR. (A) The 3&#x2032;-UTR region of <italic>H2AX</italic> contains a sequence that matches the specific binding sequences of miR-328-3p. (B) The targeting effect of miR-328-3p on <italic>H2AX</italic> 3&#x2032;-UTR was detected by a luciferase reporter assay in HOS and U2OS cells. (C) The expression levels of <italic>H2AX</italic> in HOS and HOS-2R cells were determined by western blotting. (D) The expression levels of <italic>H2AX</italic> in HOS and U2OS cells were determined by western blotting after overexpressing or silencing miR-328-3p. &#x002A;p&#x003C;0.05.</p></caption>
<graphic xlink:href="OR-39-02-0545-g02.jpg"/>
</fig>
<fig id="f4-or-39-02-0545" position="float">
<label>Figure 4.</label>
<caption><p><italic>H2AX</italic> downregulation reduces radioresistance in osteosarcoma cells. (A) To silence <italic>H2AX</italic>, si-<italic>H2AX</italic> was used, and the knockout efficiency of <italic>H2AX</italic> was detected by western blotting. (B) The survival rate of osteosarcoma cells with or without <italic>H2AX</italic> silencing after irradiation at 2 Gy. (C) The apoptosis assay was performed by flow cytometry following 2 Gy X-ray irradiation. (D) Cell viability assay was performed in si-control and si-<italic>H2AX</italic> cells after 2 Gy X-ray irradiation. &#x002A;p&#x003C;0.05.</p></caption>
<graphic xlink:href="OR-39-02-0545-g03.jpg"/>
</fig>
<fig id="f5-or-39-02-0545" position="float">
<label>Figure 5.</label>
<caption><p>miR-328-3p regulates the radiosensitivity of osteosarcoma cells by targeting <italic>H2AX</italic>. (A) The expression levels of miR-328-3p were detected by qPCR in HOS and H2OS cells cotransfected with ASO control, miR-328-3p ASO, miR-328-3p ASO&#x002B;si-control, and miR-328-3p ASO&#x002B;si-<italic>H2AX</italic>. (B) The expression levels of <italic>H2AX</italic> were detected by western blotting after silencing miR-328-3p in HOS and H2OS cells. (C) Apoptosis was detected by flow cytometry in HOS and H2OS cells. (D) Cell viability was examined by MTT assays in HOS and H2OS cells. &#x002A;p&#x003C;0.05.</p></caption>
<graphic xlink:href="OR-39-02-0545-g04.jpg"/>
</fig>
<fig id="f6-or-39-02-0545" position="float">
<label>Figure 6.</label>
<caption><p>Modulation of miR-328-3p regulates the radiosensitivity of osteosarcoma in mice. To explore the role of miR-328-3p in regulating osteosarcoma <italic>in vivo</italic>, a subcutaneously injected mouse model was established. Tumor volume and tumor weight were measured. &#x002A;p&#x003C;0.05.</p></caption>
<graphic xlink:href="OR-39-02-0545-g05.jpg"/>
</fig>
</floats-group>
</article>